scholarly journals Association between serum lactate dehydrogenase and 60‐day mortality in Chinese Hakka patients with acute myeloid leukemia: A cohort study

2021 ◽  
Author(s):  
Zuomiao Xiao ◽  
Rongpeng Gong ◽  
Xianchun Chen ◽  
Dejun Xiao ◽  
Shi Luo ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cohort Study ◽  
Lactate Dehydrogenase ◽  
Myeloid Leukemia ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Acute Myeloid

scholarly journals Chromosomal Characteristics and Prognostic Analysis of Secondary Acute Myeloid Leukemia

2021 ◽  
Author(s):  
Mingzhu Song ◽  
Tun Zhang ◽  
Dongdong Yang ◽  
Hao Xiao ◽  
Huiping Wang ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Hematologic Malignancies ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Secondary Acute Myeloid Leukemia ◽  
Prognostic Analysis ◽  
Chromosomal Karyotype ◽  
Acute Myeloid ◽  
Chromosome Karyotype

Abstract BackgroundSecondary Acute Myeloid Leukemia (S-AML) patients generally have a poor prognosis, and the chromosomal karyotype of S-AML have been rarely reported in the published literature. We aimed to explore the chromosomal karyotype and its clinical significance in patients with S-AML.MethodsClinical characteristics and chromosome karyotypes of 26 patients with S-AML were retrospectively analyzed. The overall survival (OS) was measured from the time of the patients’ transition to AML (which means the time of S-AML diagnosis) .ResultsAmong the 26 S-AML patients, there were 13 males and 13 females, with a median age of 63 years old (range, 20-77 years old). All of them were secondary to a variety of hematologic malignancies or solid tumors, and most of them were secondary to myelodysplastic syndrome (MDS). About 62% of the S-AML patients showed chromosome abnormalities. The level of serum lactate dehydrogenase (LDH) in S-AML patients with abnormal chromosome karyotype was higher than those with normal chromosome karyotype. Apart from the differences in treatment regimens, S-AML patients with chromosomal karyotype abnormalities had shorter OS (P<0.05). ConclusionsS-AML patients with abnormal chromosomal karyotype have higher LDH and shorter OS than normal chromosomal karyotype, and the OS of hypodiploidy was much shorter than hyperdiploid.

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

2009 ◽  
Vol 27 (1) ◽  
pp. 61-69 ◽  
Author(s):  
Thomas Büchner ◽  
Wolfgang E. Berdel ◽  
Claudia Haferlach ◽  
Torsten Haferlach ◽  
Susanne Schnittger ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Dose Response ◽  
Myeloid Leukemia ◽  
Standard Dose ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
High Dose ◽  
Age Related ◽  
Wbc Count ◽  
Acute Myeloid

PurposeThe purpose of the study was to assess the contribution of age and disease variables to the outcome of untreated patients with acute myeloid leukemia (AML) receiving varying intensive induction chemotherapy.Patients and MethodsPatients 16 to 85 years of age with primary AML, known karyotype, and uniform postremission chemotherapy enrolled onto two consecutive trials were eligible and were randomly assigned to induction either with a standard-dose (cytarabine, daunorubicin, and 6-thioguanine) and a high-dose (cytarabine and mitoxantrone) combination, or with two courses of the high-dose combination. Subgroups were defined by karyotype, nucleophosmin and FLT3 mutation, WBC count, serum lactate dehydrogenase, and residual blasts.ResultsIn 1,284 patients, the overall survival at 4 years in those younger and older than 60 years was 37% versus 16% (P < .001) and the ongoing remission duration was 46% versus 22% (P < .001). Similar age-related differences in outcome were found for all defined subgroups. No difference in outcome according to randomly assigned treatment regimen was observed in any age group or prognostic subset. Regarding prognostic subgroups, molecular factors were also considered.ConclusionUnder harmonized conditions, older and younger patients with AML show modest differences in their risk profiles and equally no dose response to intensified chemotherapy. Their observed fundamental difference in outcome across all subgroups remains unexplained. Further molecular investigation may elucidate the age effect in AML and identify new targets.

scholarly journals Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study

Leukemia ◽  
2021 ◽  
Author(s):  
Neel S. Bhatt ◽  
Malek J. Baassiri ◽  
Wei Liu ◽  
Nickhill Bhakta ◽  
Wassim Chemaitilly ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cohort Study ◽  
Myeloid Leukemia ◽  
Childhood Acute Myeloid Leukemia ◽  
Acute Myeloid

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

Blood ◽  
2009 ◽  
Vol 113 (19) ◽  
pp. 4505-4511 ◽  
Author(s):  
Verena Ingeborg Gaidzik ◽  
Richard Friedrich Schlenk ◽  
Simone Moschny ◽  
Annegret Becker ◽  
Lars Bullinger ◽  
...  
Keyword(s):  
Overall Survival ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Negative Impact ◽  
Serum Lactate Dehydrogenase ◽  
Study Group ◽  
Prognostic Impact ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Acute Myeloid

AbstractTo evaluate the incidence and clinical impact of WT1 gene mutations in younger adult patients with cytogenetically normal acute myeloid leukemia (CN-AML), sequencing of the complete coding region was performed in diagnostic samples from 617 patients who were treated on 3 German-Austrian AML Study Group protocols. WT1 mutations were identified in 78 (12.6%) of the 617 patients; mutations clustered in exon 7 (54 of 78) and exon 9 (13 of 78), but also occurred in exons 1, 2, 3, and 8. WT1 mutations were significantly associated with younger age, higher serum lactate dehydrogenase levels, higher blood blast counts, and the additional presence of FLT3-ITD (P < .001) and CEBPA mutations (P = .004). There was no difference in relapse-free survival and overall survival between patients with (WT1mut) or without WT1 mutations. Subset analysis showed that patients with the genotype WT1mut/FLT3-ITDpos had a lower complete remission rate (P = .003) and an inferior relapse-free survival (P = .006) and overall survival (P < .001) compared with those with the genotype WT1mut/FLT3-ITDneg. In conclusion, in our large cohort of younger adults with CN-AML, WT1 mutation as a single molecular marker did not impact on outcome. However, our data suggest a negative impact of the genotype WT1mut/FLT3-ITDpos.

Sign in / Sign up

Export Citation Format

Share Document